132 related articles for article (PubMed ID: 19212686)
21. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
van Haperen VW; Veerman G; Vermorken JB; Pinedo HM; Peters G
Biochem Pharmacol; 1996 Apr; 51(7):911-8. PubMed ID: 8651941
[TBL] [Abstract][Full Text] [Related]
22. Frondoside A enhances the antiproliferative effects of gemcitabine in pancreatic cancer.
Al Shemaili J; Mensah-Brown E; Parekh K; Thomas SA; Attoub S; Hellman B; Nyberg F; Adem A; Collin P; Adrian TE
Eur J Cancer; 2014 May; 50(7):1391-8. PubMed ID: 24462376
[TBL] [Abstract][Full Text] [Related]
23. Cyclopentenyl cytosine primes SK-N-BE(2)c neuroblastoma cells for cytarabine toxicity.
Bierau J; Van Gennip AH; Leen R; Helleman J; Caron HN; Van Kuilenburg AB
Int J Cancer; 2003 Jan; 103(3):387-92. PubMed ID: 12471622
[TBL] [Abstract][Full Text] [Related]
24. In vitro inhibition of cytidine triphosphate synthetase activity by cyclopentenyl cytosine in paediatric acute lymphocytic leukaemia.
Verschuur AC; Van Gennip AH; Leen R; Meinsma R; Voute PA; van Kuilenburg AB
Br J Haematol; 2000 Jul; 110(1):161-9. PubMed ID: 10930994
[TBL] [Abstract][Full Text] [Related]
25. The effect of cyclopentenyl cytosine on human SK-N-BE(2)-C neuroblastoma cells.
Slingerland RJ; Van Gennip AH; Bodlaender JM; Voûte PA; Van Kuilenburg AB
Biochem Pharmacol; 1995 Jul; 50(2):277-9. PubMed ID: 7632174
[TBL] [Abstract][Full Text] [Related]
26. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
[TBL] [Abstract][Full Text] [Related]
27. Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system.
Yu WD; Ma Y; Flynn G; Muindi JR; Kong RX; Trump DL; Johnson CS
Cell Cycle; 2010 Aug; 9(15):3022-9. PubMed ID: 20699664
[TBL] [Abstract][Full Text] [Related]
28. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.
Iwanski GB; Lee DH; En-Gal S; Doan NB; Castor B; Vogt M; Toh M; Bokemeyer C; Said JW; Thoennissen NH; Koeffler HP
Br J Pharmacol; 2010 Jun; 160(4):998-1007. PubMed ID: 20590594
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.
Bauer C; Bauernfeind F; Sterzik A; Orban M; Schnurr M; Lehr HA; Endres S; Eigler A; Dauer M
Gut; 2007 Sep; 56(9):1275-82. PubMed ID: 17395611
[TBL] [Abstract][Full Text] [Related]
30. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
[TBL] [Abstract][Full Text] [Related]
31. Cyclopentenylcytosine triphosphate. Formation and inhibition of CTP synthetase.
Kang GJ; Cooney DA; Moyer JD; Kelley JA; Kim HY; Marquez VE; Johns DG
J Biol Chem; 1989 Jan; 264(2):713-8. PubMed ID: 2910861
[TBL] [Abstract][Full Text] [Related]
32. Measurement of cyclopentenyl cytosine 5'-triphosphate in vitro and in vivo by multidimensional high-performance liquid chromatography.
Agbaria R; Ford H; Kelley JA; Xie F; Politi P; Grem JL; Cooney DA; Marquez VE; Allegra CJ; Johns DG
Anal Biochem; 1993 Aug; 213(1):90-6. PubMed ID: 8238887
[TBL] [Abstract][Full Text] [Related]
33. Synergistic effects of deuterium oxide and gemcitabine in human pancreatic cancer cell lines.
Bader Y; Hartmann J; Horvath Z; Saiko P; Grusch M; Madlener S; Maier S; Oehler L; Fritzer-Szekeres M; Heller N; Alken RG; Krupitza G; Szekeres T
Cancer Lett; 2008 Feb; 259(2):231-9. PubMed ID: 18023527
[TBL] [Abstract][Full Text] [Related]
34. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.
Wang YW; Wang SJ; Zhou YN; Pan SH; Sun B
J Cancer Res Clin Oncol; 2012 May; 138(5):785-97. PubMed ID: 22270965
[TBL] [Abstract][Full Text] [Related]
35. Gemcitabine as a radiosensitizer in undifferentiated tumors.
Kal HB; El Sharouni SY; Barten-van Rijbroek AD
Anticancer Res; 2006; 26(1A):139-45. PubMed ID: 16475690
[TBL] [Abstract][Full Text] [Related]
36. Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line.
Kazuno H; Sakamoto K; Fujioka A; Fukushima M; Matsuda A; Sasaki T
Cancer Sci; 2005 May; 96(5):295-302. PubMed ID: 15904471
[TBL] [Abstract][Full Text] [Related]
37. Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.
Kazim S; Malafa MP; Coppola D; Husain K; Zibadi S; Kashyap T; Crochiere M; Landesman Y; Rashal T; Sullivan DM; Mahipal A
Mol Cancer Ther; 2015 Jul; 14(7):1570-81. PubMed ID: 25934708
[TBL] [Abstract][Full Text] [Related]
38. Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer.
Blaauboer A; Booy S; van Koetsveld PM; Karels B; Dogan F; van Zwienen S; van Eijck CHJ; Hofland LJ
BMC Cancer; 2020 Sep; 20(1):913. PubMed ID: 32967656
[TBL] [Abstract][Full Text] [Related]
39. Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway.
Bu HQ; Luo J; Chen H; Zhang JH; Li HH; Guo HC; Wang ZH; Lin SZ
Int J Oncol; 2012 Sep; 41(3):949-58. PubMed ID: 22710877
[TBL] [Abstract][Full Text] [Related]
40. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine.
Kimura K; Sawada T; Komatsu M; Inoue M; Muguruma K; Nishihara T; Yamashita Y; Yamada N; Ohira M; Hirakawa K
Clin Cancer Res; 2006 Aug; 12(16):4925-32. PubMed ID: 16914581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
